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Beyond High-Density Lipoprotein Cholesterol Levels
Evaluating High-Density Lipoprotein Function
as Influenced by Novel Therapeutic Approaches
Emil M. deGoma, MD,* Rolando L. deGoma, MD,† Daniel J. Rader, MD‡
Stanford, California; Trenton, New Jersey; and Philadelphia, Pennsylvania
A number of therapeutic strategies targeting high-density lipoprotein (HDL) cholesterol and reverse cholesterol
transport are being developed to halt the progression of atherosclerosis or even induce regression. However, cir-
culating HDL cholesterol levels alone represent an inadequate measure of therapeutic efficacy. Evaluation of the
potential effects of HDL-targeted interventions on atherosclerosis requires reliable assays of HDL function and
surrogate markers of efficacy. Promotion of macrophage cholesterol efflux and reverse cholesterol transport is
thought to be one of the most important mechanisms by which HDL protects against atherosclerosis, and meth-
ods to assess this pathway in vivo are being developed. Indexes of monocyte chemotaxis, endothelial inflamma-
tion, oxidation, nitric oxide production, and thrombosis reveal other dimensions of HDL functionality. Robust,
reproducible assays that can be performed widely are needed to move this field forward and permit effective
assessment of the therapeutic potential of HDL-targeted therapies. (J Am Coll Cardiol 2008;51:2199–211)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.016l
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pnumber of therapeutic strategies (1,2) are being developed
o target high-density lipoprotein cholesterol (HDL-C) in an
ttempt to halt the progression or induce regression of athero-
clerosis and reduce cardiovascular events. The fidelity of the
nverse correlation between HDL-C levels and cardiovascular
isk noted in observational studies remains uncertain in the
etting of pharmacotherapy. Early assessment of changes in
igh-density lipoprotein (HDL) functionality in response to a
ew HDL-targeted therapy is critical. This article aims to
eview the limitations of circulating HDL-C as a therapeutic
nd point and to discuss emerging metrics of HDL
unctionality.
imitations of HDL-C as a Surrogate End Point
rospective cohort studies, as well as randomized controlled
rials of antidyslipidemic therapies, support a powerful inverse
orrelation between circulating HDL-C levels and coronary
isk among patients with elevated, normal, or low low-density
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008, accepted March 4, 2008.ipoprotein cholesterol (LDL-C) (3–6). However, the inverse
elationship falls short when applied to particular subgroups
ith altered lipoprotein structure and metabolism. Naturally
ccurring genetic conditions in humans indicate that lower
DL-C values need not impart excess cardiovascular risk, as in
ndividuals carrying the apolipoprotein (apo) A-I Milano
ariant, and that higher HDL-C levels may not always confer
protective benefit, as suggested by the ongoing debate
egarding the clinical significance of cholesteryl ester transfer
rotein deficiency (7–10). The recently published results of
maging studies and an outcome trial with the cholesteryl ester
ransfer protein (CETP) inhibitor torcetrapib (11–14) showed
o impact on atherosclerosis and increased morbidity and
ortality despite substantial raising of HDL-C levels, further
omplicating the picture. Elevation in blood pressure and
ldosterone levels, which are not mechanism-based effects,
uggest that off-target activities particular to torcetrapib may
ave increased cardiovascular risk (12). New CETP inhibitors
hat do not cause elevated blood pressure are in clinical
evelopment (15), and definitive answers regarding the poten-
ial therapeutic benefit of CETP inhibitors await further study.
owever, the experience with torcetrapib has fueled the
nterest in better assessment of HDL functionality to comple-
ent measures of HDL mass.
Determined simply as the amount of cholesterol in HDL
articles per 100 ml of plasma, HDL-C suffers from limita-
ions intrinsic to its static, mass-based measurement. First, as a
napshot of the steady-state cholesterol pool, HDL-C does not
irectly assess the rate of centripetal cholesterol flux from
eripheral foam cells to the liver, which is influenced by many
actors beyond the mass of HDL-C alone. Second, circulating
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Beyond HDL-C: Evaluating Functionality June 10, 2008:2199–211HDL-C values fail to convey in-
formation regarding the anti-
inflammatory, antioxidant, anti-
thrombotic, and endothelial
function promoting benefits of
HDL, despite mounting evidence
supporting the clinical significance
of these pleiotropic functions.
Importantly, the limitations of
cholesterol as a proxy for lipopro-
tein atherogenicity extend to
LDL-C as well (16). By acknowl-
edging particle heterogeneity,
measures of apolipoprotein B (17),
small dense low-density lipopro-
tein (LDL) (18), and oxidized
LDL (19) provide additional
prognostic information above and
beyond LDL-C. Newer HDL as-
says address the limitations of
HDL-C in an attempt to provide
a more accurate assessment of
HDL functionality in the setting
of pharmacotherapy.
holesterol Efflux
nd Reverse Cholesterol Transport
romotion of cholesterol efflux from macrophages and its
eturn to the liver, bile, and feces, completing the pathway
Figure 1 Reverse Cholesterol Transport
High-density lipoprotein (HDL) cholesterol promotes and facilitates the process of
to HDL and ultimately returned to the liver for excretion. Efflux to nascent and mat
terol is returned to the liver via the hepatic receptor SR-BI or by transfer to apolipo
tein (2). Figure illustrations by Rob Flewell. CETP  cholesterol ester transfer prote
scavenger receptor class B-type I; VLDL  very low-density lipoprotein.
Abbreviations
and Acronyms
CAD  coronary artery
disease
CETP  cholesteryl ester
transfer protein
FMD  flow-mediated
dilation
HDL  high-density
lipoprotein
HUVEC  human umbilical
endothelial cell
ICAM  intercellular
adhesion molecule
LDL  low-density
lipoprotein
NO  nitric oxide
NOS  nitric oxide synthase
RCT  reverse cholesterol
transport
TNF  tumor necrosis
factor
VCAM  vascular cell
adhesion moleculef “reverse cholesterol transport” (RCT), is thought to be
ne of the most important mechanisms by which HDL
rotects against atherosclerosis (Fig. 1). Evaluating the flux
f cholesterol (the rate and magnitude of intercompartmen-
al shifts) provides a dynamic measure of RCT effectiveness
nd, potentially, a more informative way of assessing the
fficacy of a novel HDL-targeted intervention.
ellular cholesterol efflux ex vivo. To assess cellular
fflux, donor cells, such as hepatoma cells, fibroblasts, or
acrophages, are first incubated with 3H-cholesterol
20,21). Incubation with a medium containing an “acceptor”
lipid-free apoA-I, isolated HDL, or diluted human serum)
s carried out, and after multiple washings, scintigraphy
uantifies the radioactivity in the medium and associated
ith the cells. Cholesterol efflux is then expressed as the
mount of label released into the medium divided by the
otal label present. Acceptors in the medium and donor cells
an be manipulated to examine the effects of genetic and
harmacologic manipulation on efflux potential. Manipula-
ion of donor cells may augment cholesterol efflux. Mouse
eritoneal macrophages overexpressing ABCA1 efflux cho-
esterol to apoA-I faster than do wild-type control cells, an
ffect associated with smaller, less complex aortic valvular
therosclerotic lesions in transgenic ABCA1 mice (22). In
umans, investigation of families with ABCA1 mutations
emonstrated an inverse correlation between cholesterol
fflux from primary fibroblasts and carotid intima-media
hickness (23). Administration of a liver X receptor agonist
o macrophages results in increased cholesterol efflux, at
e cholesterol transport (RCT), whereby excess macrophage cholesterol is effluxed
L occurs via the transporters ABCA1 and ABCG1, respectively. The HDL choles-
n (apo) B–containing lipoproteins by the action of cholesteryl ester transfer pro-
L  low-density lipoprotein; LDL-R  low-density lipoprotein receptor; SR-BI revers
ure HD
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June 10, 2008:2199–211 Beyond HDL-C: Evaluating Functionalityeast in part through the ABCA1 pathway (24,25). How-
ver, the most applicable approach of ex vivo efflux assays to
rug development would be to use whole serum or isolated
DL from subjects treated with an experimental drug and
est its ability to promote cholesterol efflux from a defined
ell system ex vivo.
Pre-clinical studies support the concept that augmenting
he ability of serum or HDL to promote the efflux of
holesterol from cells may confer an atheroprotective ben-
fit. Administration of recombinant apoA-I Milano or oral
-4F, a small apoA-I mimetic peptide, significantly in-
reased the cholesterol efflux-promoting capacity of plasma
aken from treated apoE-deficient mice (26,27). These ex
ivo findings were associated with decreased macrophage
nd lipid content of aortic atheroma, indicating enhanced
obilization of tissue cholesterol (27,28).
Interestingly, treatment with torcetrapib resulted in en-
anced efflux capacity of HDL, whether normalized to
olume of serum or to HDL mass (29). However, there are
ew data that link serum efflux capacity to atherosclerosis or
ardiovascular events in humans. One relatively small pro-
pective study of men referred for coronary angiography (30)
emonstrated that efflux capacity correlated with cardiovas-
ular outcomes and all-cause mortality during a 4.5-year
ollow-up. For an intervention that is expected to influence
irculating HDL or whole serum in such a way as to
Figure 2 Macrophage-Specific Reverse Cholesterol Transport In
(A) To assay macrophage-specific RCT, the critical atheroprotective pathway, a rec
prepared macrophages after injection. Macrophages are cholesterol-loaded with ac
cholesterol. Loaded and labeled macrophages are then injected intraperitoneally in
taining HDL acceptor particles. Subsequently, blood is sampled at several time po
3H-steroid. The fecal excretion of 3H-steroid is a measure of macrophage-to-feces
control (null) adenovirus vector (n  10). Three days after vector injection, 3H-chol
overexpressing apoA-I demonstrated significantly higher levels of 3H-tracer in plasm
groups. Reprinted, with permission, from Zhang et al. (33). Figure illustrations by Renerate greater “efflux potential,” ex vivo assessment of the
holesterol efflux capacity of isolated HDL or diluted serum
ay provide important information regarding the efficacy of
he intervention. However, a limitation of efflux potential as
surrogate measure is its inability to assess terminal seg-
ents of the RCT pathway or effects of interventions that
re directed toward the cells themselves. There is also a need
o determine the different pathways that contribute to total
fflux to serum and how these vary among individuals.
inally, there is a need for additional data linking serum
fflux capacity to atherosclerosis progression and clinical
utcomes.
acrophage-specific RCT in vivo. To assay macrophage-
pecific RCT, the critical atheroprotective pathway, a re-
ently developed technique in mice follows the fate of
adiolabeled cholesterol from prepared macrophages after
njection (Fig. 2A). Macrophages are cholesterol-loaded
ith acetylated LDL to become foam cells and labeled with
H-cholesterol. Loaded and labeled macrophages are then
njected intraperitoneally into mice, where they remain in
he peritoneal cavity bathed in peritoneal fluid containing
DL acceptor particles. Subsequently, blood is sampled at
everal time points, feces are collected continuously over
8 h, and plasma and feces are assayed for 3H-steroid. The
ecal excretion of 3H-steroid is a measure of macrophage-
o-feces RCT. The initial experiments employing this
eveloped technique (33) follows the fate of radiolabeled cholesterol from
d low-density lipoprotein (LDL) to become foam cells and labeled with 3H-
e, where they remain in the peritoneal cavity bathed in peritoneal fluid con-
nd feces and plasma are collected continuously over 48 h and assayed for
B) C57BL/6 mice were injected intravenously with apoA-I adenovirus (n  10) or
l-labeled J774 foam cells were injected. Compared with control subjects, mice
8 h and in liver and feces. *p  0.05 between control and apoA-I adenovirus
well. Abbreviations as in Figure 1.Vivo
ently d
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Beyond HDL-C: Evaluating Functionality June 10, 2008:2199–211echnique used the murine J774 macrophage cell line to
xamine the effect of apoA-I overexpression achieved with a
ecombinant adenoviral vector. In contrast to prior studies
easuring total centripetal flux (31,32), this macrophage-
pecific approach indicated increased macrophage RCT
ith apoA-I overexpression, consistent with the atheropro-
ective role of apoA-I (33). Compared with control subjects,
ice overexpressing apoA-I demonstrated significantly
igher levels of 3H-tracer in plasma, liver, and feces after
8 h (Fig. 2B). Importantly, the majority of plasma 3H-
holesterol was detected in the HDL fraction. These results
uggest that 3H-cholesterol originating in cholesterol-
oaded macrophages was transported through the plasma,
ia HDL and not migration of intact macrophages, to the
iver and then ultimately excreted into the feces, providing
irect support for the RCT hypothesis. Subsequent studies
emonstrated that apoA-I–deficient mice, on an atheroscle-
otic background, had markedly reduced macrophage RCT
espite similar HDL-C levels, demonstrating the impor-
ance of apoA-I in RCT and potentially explaining the
ncreased atherosclerosis in these mice (34).
Additional studies have assessed macrophage-specific
CT in the setting of pharmacologic and genetic manipu-
ation of the host animal. Pharmacologic activation of liver
receptor, which up-regulates the cellular efflux transport-
rs ABCA1 and ABCG1, was shown to promote macro-
hage RCT (35). Overexpression of the hepatic SR-BI, a
eceptor mediating selective uptake of cholesterol from
DL enhanced macrophage-specific RCT despite reduced
DL-C levels, whereas hepatic SR-BI deficiency was
ssociated with markedly impaired macrophage RCT in the
etting of elevated HDL-C levels (36). ABCA1-knockout
ice demonstrated significantly impaired macrophage-
pecific RCT, manifesting 2- to 3-fold reductions in 3H-
racer in collected feces and liver (37). This approach has
lso been adapted to use primary mouse peritoneal and bone
arrow–derived macrophages, enabling the use of macro-
hages from knockout mice to test the role of macrophage-
pecific genes. For example, macrophages deficient in
BCA1 demonstrated impaired RCT in vivo (24,38).
urthermore, increased macrophage expression of ABCG1,
mediator of efflux to mature HDL in vitro, significantly
romoted macrophage RCT in vivo, whereas knockdown
nd knockout of macrophage ABCG1 impaired macro-
hage RCT in vivo (24). Manipulating macrophage SR-BI
xpression, on the other hand, did not affect macrophage-
pecific RCT, highlighting the varied role of lipid trans-
orters across different cell types (24).
Recent experiments examining the effect of CETP in
ice, which naturally lack this enzyme, offer new insights
nto the contrasting roles of CETP in RCT (39). In the
pobec-1-null mouse model, which exhibits apoB-
ipoprotein metabolism similar to humans, CETP expres-
ion achieved via hepatic transduction significantly in-
reased tracer excretion in feces while effecting a substantial
eduction in HDL-C. On the other hand, apobec-1/LDL- ieceptor double-knockout mice failed to exhibit enhanced
acrophage-specific RCT in the setting of CETP expres-
ion, indicating that the effects of CETP on RCT depend
n the efficiency of downstream cholesteryl ester clearance
y apoB-lipoprotein pathways. These results suggest that in
nimals or humans with highly effective LDL clearance,
ETP may enhance RCT and serve an atheroprotective
ole, but when LDL clearance is impaired, CETP may be
roatherogenic. Regardless of the ultimate fate of CETP
nhibitors, the ability of the macrophage-specific assay to
etect changes in RCT arising from perturbations in the
etabolic milieu supports the assay’s utility as both a tool
or studying RCT pathways and as a viable pre-clinical
urrogate for HDL functionality. Macrophage-specific as-
ays have been useful in mice; however, their applicability to
umans remains uncertain. Thus, methods for assessing
ntegrated RCT in humans are still needed.
entripetal cholesterol flux estimated from peripheral
ynthesis and uptake. A technique to measure net centrip-
tal movement of cholesterol from the periphery in animals
as developed on the assumption that peripheral cholesterol
gress is equal to peripheral cholesterol acquisition via de
ovo synthesis and LDL-C uptake (40,41). Dual radioiso-
ope techniques employ labeled cholesterol precursors and
DL-C, administered orally or intravenously, to monitor
holesterol synthesis in and LDL-C transport to extrahe-
atic organs. Provided no net change occurs within periph-
ral cholesterol pools, the sum of these 2 input contributions
pproximates the rate of egress of cholesterol from the
eriphery. Conclusions drawn from this assay rely on the
remise that cholesterol returning to the liver necessarily
epresents a positive outcome. Increased hepatic delivery
ay not be atheroprotective, however, if hepatocytes fail to
liminate cholesterol in feces and instead reroute lipid into
lasma as LDL and very LDL (42). It is also possible that
acrophage cholesterol represents a small compartment
ensitive to factors that do not have major effects on the
verall transport of cholesterol from the periphery to the
iver. Unique attributes of the macrophage cholesterol pool
ay be the explanation for the failure of this method to
etect a difference in centripetal cholesterol flux in mice
ith markedly different levels of HDL-C and apoA-I
31,32,40,41).
ass fecal steroid excretion. Measurement of fecal cho-
esterol excretion, the final common pathway of centripetal
ow, theoretically could provide an in vivo proxy of net
CT effectiveness suitable for both pre-clinical and clinical
tudies. Cholesterol is eliminated via bile into the feces
ither through direct secretion or following conversion to
ile acids in the liver. Quantifying both neutral and acidic
teroid fractions in collected fecal samples using gas-liquid
hromatography, followed by correction for variability in
ecal flow with simultaneous measurement of a nonabsorb-
ble sterol, may yield a measure of total centripetal flux (43).
nterventions that augment fecal cholesterol content, by
nference, stimulate RCT and may confer an atheroprotec-
t
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June 10, 2008:2199–211 Beyond HDL-C: Evaluating Functionalityive benefit. In support of this surrogate, infusion of full-
ength human apoA-I not only increased the acceptor
article prebeta HDL (44) but also increased fecal steroid
xcretion when administered in human studies (45). On the
ther hand, incongruent results from knockout mice high-
ight concerns regarding assessment of total centripetal flux
ia fecal steroid excretion. Although numerous experiments
rmly establish the role of ABCA1 as a pivotal mediator of
holesterol efflux, fecal steroid excretion was normal in
BCA1 knockout mice (31,32). Inadequate sensitivity may
imit interpretation of fecal steroid excretion as a surrogate
or RCT. A critical distinction exists between total centrip-
tal flow and macrophage-specific RCT. Given the minute
ontribution of atheroma to total exchangeable cholesterol
ody stores, quantifying fecal cholesterol content may fail to
etect even significant changes in cholesterol traffic from
acrophage foam cells to hepatocytes (46). Furthermore,
ultiple factors contribute to fecal steroid excretion, and a
rug that promotes RCT may induce counter-regulatory
Figure 3 Kinetic Modeling of Cholesterol Efflux From Tissues In
The flow of cholesterol from tissue to plasma, which encompasses the first step i
infused directly into the plasma compartment until steady-state levels are attained
beled) cholesterol from tissues into plasma. At the isotopic plateau, the rate of ap
rate of tracer infusion divided by the plasma molar percent enrichment with labeleactors that limit fecal steroid excretion in steady state. Thus,
lthough fecal steroid excretion might be useful in an acute
ntervention such as apoA-I infusion, it is less likely to be useful
n a chronic intervention intended to promote RCT.
inetic modeling of cholesterol efflux from tissues in
ivo by isotope dilution. A recently developed approach
47,48) may permit in vivo assessment of individual com-
onents of intact RCT in humans. The steady-state isotope
ilution principle, a method initially applied to the study of
mino acid metabolism, provides the conceptual foundation.
n brief, the kinetic model considers 2 distinct cholesterol
ompartments: a slowly exchanging extrahepatic tissue cho-
esterol pool and a rapidly exchanging plasma-hepatic cho-
esterol pool (Fig. 3). The flow of cholesterol from tissue to
lasma, which encompasses the first step in RCT, can be
ssessed in vivo by noting the dilution of exogenous labeled
holesterol infused directly into the plasma compartment
ntil steady-state levels are attained. The tracer abundance
n plasma is diluted by the efflux of endogenous (unlabeled)
by Isotope Dilution
can be assessed in vivo by noting the dilution of exogenous labeled cholesterol
8). The tracer abundance in plasma is diluted by the efflux of endogenous (unla-
nce of endogenous cholesterol, representing tissue cholesterol efflux, equals the
esterol. Figure illustrations by Rob Flewell. Abbreviations as in Figure 1.Vivo
n RCT,
(47,4
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Beyond HDL-C: Evaluating Functionality June 10, 2008:2199–211holesterol from tissues into plasma. At the isotopic plateau,
he rate of appearance of endogenous cholesterol, represent-
ng tissue cholesterol efflux, equals the rate of tracer infusion
ivided by the plasma molar percent enrichment with
abeled cholesterol.
Presentation of preliminary human studies using 13C-
holesterol demonstrated feasibility, revealing that an 18-h
nfusion period was required to achieve plateau tracer levels
nd reproducible measurements of tissue cholesterol efflux
48). Although this method requires validation and has not
et been published in a peer-reviewed journal, it may have
tility in assessing RCT following pharmacologic interven-
ion. However, its ability to specifically assess peripheral
issue cholesterol efflux depends on successful equilibration
f the infused tracer with hepatic cholesterol, an issue
ifficult to prove in humans. Otherwise, efflux of unlabeled
holesterol from the liver could contribute to the dilution of
he tracer in plasma. Furthermore, this method measures
otal peripheral efflux rather than the small pool from
acrophages. Whether a consistent relationship exists be-
ween total tissue cholesterol flux and macrophage-specific
CT remains to be determined.
ndexes of Anti-Inflammatory
nd Antioxidant Activity
igh-density lipoprotein cholesterol exerts a number of
otentially antiatherogenic effects independent of choles-
erol efflux and centripetal transport, including inhibiting
ipid oxidation, impairing leukocyte adhesion and monocyte
ctivation, promoting nitric oxide (NO) production and
ow-induced vasodilation, preventing endothelial cell dam-
ge and death, and inhibiting activation of platelets and the
oagulation cascade (Fig. 4) (49,50). However, the clinical
ignificance of these varied functions remains unclear. The
nti-inflammatory activities of HDL have generated the
ost excitement, prompted by conclusive evidence impli-
ating LDL modification and monocyte migration, 2 inter-
elated processes, in the critical first steps of atherogenesis.
ndothelial adhesion molecule expression. To gain entry
nto the subendothelial space, monocytes must first arrest
heir passage through the circulation. Adhesion molecules
resented on the luminal surface of endothelial cells slow
eighboring monocytes, first via loose tethering mediated by
-selectin and then by tight association of endothelial
ntercellular adhesion molecule (ICAM)-1 and vascular cell
dhesion molecule (VCAM)-1 with leukocyte integrins
51,52). Expression of adhesion molecules represents a
ynamic process, activated by inflammatory cytokines (53)
nd vascular injury (54) and up-regulated in atherosclerosis
n both animals (55) and humans (56,57). As data implicate
ncreased endothelial expression of adhesion molecules in
therosclerotic disease (58), in vitro assays have been devel-
ped to evaluate the effect of HDL on this particular facet
f endothelial activation (59). In one model, endothelial
ells are incubated with test HDL, followed by stimulation aith a proinflammatory agent such as tumor necrosis factor
TNF)-alpha. Labeled antibodies specific for each adhesion
olecule of interest are then added and flow cytometry
nalysis performed to determine levels of expression. The
riginal experiment using human umbilical endothelial cells
HUVECs) demonstrated the ability of HDL obtained
rom healthy donors to inhibit cytokine-mediated protein
xpression of VCAM-1, ICAM-1, and E-selectin (59).
ubsequent in vitro studies have established the ability of
ative and reconstituted HDL to down-regulate inducible
xpression of adhesion molecules (60–62), with a few
xceptions (63). Reasons for these conflicting results remain
nclear; however, the majority of in vitro data support a role
f HDL in the inhibition of endothelial activation.
In vivo pre-clinical studies of endothelial expression of
dhesion molecules may provide additional methods for
valuating HDL-directed therapeutics. Following carotid
njury by surgical placement of a periadvential cuff, HDL
nfusion decreased local ICAM- and VCAM-1 expression
n both rabbits (64) and mice (65). Suppression of adhesion
olecules was associated with decreased leukocyte infiltra-
ion (64) and neointimal hyperplasia (65), recognized steps
n atherogenesis. Importantly, suppression of endothelial
xpression of adhesion molecules in vivo, which has been
Figure 4 HDL Functions Other Than
Reverse Cholesterol Transport
High-density lipoprotein exerts a number of potentially antiatherogenic effects
independent of cholesterol efflux and centripetal transport, including inhibiting
lipid oxidation, impairing leukocyte adhesion and monocyte activation, promot-
ing nitric oxide (NO) production and flow-induced vasodilation, preventing endo-
thelial cell damage and death, and inhibiting activation of platelets and the
coagulation cascade. The clinical significance of these varied functions
remains unclear. Figure illustrations by Rob Flewell. Abbreviations as in Figures
1 and 2.ssociated with decreased atherosclerosis (66,67), appears to
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June 10, 2008:2199–211 Beyond HDL-C: Evaluating Functionalityorrelate with in vitro findings. Reconstituted HDL inhib-
ted expression of interleukin-1–induced E-selectin both in
itro by porcine aortic endothelial cells and in vivo by
ubcutaneous microvascular endothelial cells, as measured
y radiolabeled antibodies specific for E-selectin (68). Ad-
inistration of the apoA-I mimetic peptide L-4F, associ-
ted with reduced atheroma formation in dyslipidemic
ouse models prone to atherosclerosis (69), reduced
UVEC expression of VCAM-1 in a dose-dependent
ashion (70). In a clinical study, consumption of saturated
at, a known atherogenic diet (71), significantly impaired
he ability of HDL to suppress TNF-alpha–induced expres-
ion of ICAM- and VCAM-1 on HUVECs (72). Con-
ersely, polyunsaturated fat, which population studies sug-
est may offer protection against atherosclerosis (71,73),
nhanced HDL-mediated endothelial inhibition. However,
he reliability and reproducibility of the in vitro assay of
nhibition of endothelial adhesion molecule expression as a
urrogate measure of the antiatherogenic functionality of
DL remains to be established, and standardized and
alidated assays are needed.
onocyte chemotaxis. To characterize the anti-inflammatory
r proinflammatory potential of HDL, a cell-based assay
easures the effect of HDL on monocyte chemotactic
ctivity, the propensity of monocytes to migrate into the
ubendothelial space (74). This coculture model provides a
imulated arterial wall consisting of a confluent human
ortic endothelial cell monolayer and smooth muscle cell
ultilayer separated by a layer of collagen. The endothelial
ell monolayer is first incubated with standard control LDL
r oxidized phospholipids, stimulants of monocyte chemo-
axis, in the presence or absence of test HDL. Human
eripheral blood monocytes are subsequently added to the
ndothelial side of the coculture and visualized by the
ddition of antimonocyte antibodies. Finally, monocytes
hat migrated into the subendothelial space are counted.
esults obtained from coculture incubation with test HDL
an be divided by those following addition of control LDL
lone to yield an “HDL inflammatory index,” with values
bove 1 indicating proinflammatory HDL and values below
denoting anti-inflammatory HDL (75).
Studies of pharmacologic intervention and genetic ma-
ipulation in mouse models support the utility of indexes of
onocyte migration. In LDL receptor and apoE knockout
ice, orally administered D-4F, an apoA-I mimetic pep-
ide, significantly decreased both monocyte migration and
therosclerotic burden (76,77). A peptide derived from
poJ, an inhibitor of LDL oxidation and the terminal
omplement cascade, yielded similar outcomes in mouse
odels and provided additional support to an association
etween impaired monocyte chemotactic activity and re-
uced atherosclerosis (78). Absence of phospholipid transfer
rotein attenuates the proatherogenic effect of LDL recep-
or deficiency in mice in part through enhancing the ability
f the HDL to reduce monocyte chemotaxis (79). sAn interesting human study (75) compared HDL inflam-
atory indexes in healthy control subjects and patients with
oronary artery disease (CAD) before and after statin
herapy. High-density lipoprotein cholesterol taken from
ge- and gender-matched healthy control patients decreased
onocyte chemotaxis, yielding a mean inflammatory index
f 0.38. Patients with CAD, however, exhibited pro-
nflammatory HDL augmenting monocyte transmigration
ore than control LDL alone, with a mean index of 1.38.
dministration of simvastatin significantly reduced the
nflammatory index to 1.08, suggesting improvement of
DL anti-inflammatory function with statin therapy. In
ddition, the study evaluated monocyte chemotaxis in CAD
atients with elevated HDL-C levels (mean 95 mg/dl) in an
ttempt to explain the apparent discrepancy. The HDL
btained from this group was pro-inflammatory with an
ndex of 1.28, highlighting the limitations of HDL-C alone
nd the importance of functional metrics. Although this
ssay is conceptually attractive and has been validated in
everal settings, it may be cumbersome to use as a routine
ssay for assessing HDL anti-inflammatory function.
ntioxidant activity. The interplay between LDL oxida-
ion and atherogenesis may provide additional opportunities
or functional metrics of HDL. Oxidized LDL has a variety
f proatherogenic effects (80). High-density lipoprotein
holesterol has been shown to inhibit LDL oxidation in
itro (81,82). The HDL-associated enzymes paraoxonase
nd glutathione selenoperoxidase have been suggested to
lay a role in this activity of HDL (83). As with its ability
o impede monocyte chemotaxis, the antioxidant function-
lity of HDL is dynamic and can be enhanced or diminished
y altering the metabolic milieu (84).
One recently developed assay (85) measures integrated
DL antioxidant potential, using physiologic phospholip-
ds known to participate in LDL modification (Fig. 5A). In
he presence of dichlorofluorescein, a fluorescent marker of
ipid oxidation products, HDL is added to various phos-
holipids found in oxidized LDL to determine its ability to
nactivate or prevent the formation of biologically active
xidized phospholipids. After the reagents are combined,
pectroscopy permits quantification of net oxidation, with
iminished fluorescence intensity signaling fewer oxidized
hospholipids and suggesting a more antiatherogenic HDL.
vidence for an inverse association between atherosclerosis
nd net antioxidant activity determined by this assay comes
rom several studies. High-density lipoprotein from CAD
atients yields significantly higher levels of oxidation prod-
cts compared with that of healthy control patients (85). As
ith indexes of monocyte chemotaxis, treatment with simva-
tatin attenuates the oxidation activity of HDL in CAD
atients but fails to restore its antioxidant ability (Fig. 5B) (75).
imilarly, studies of oral D-4F as well as of an apoJ peptide in
ice (76–78) reveal concordance between oxidation and
onocyte migration and a negative association between these
urrogates and atherosclerosis. This relatively simple cell-free
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o high-throughput assessment of HDL antioxidant function
n response to therapeutic intervention.
O Production and Endothelial Function
uiescent endothelium produces NO, which acts to silence
ellular pathways of inflammation, proliferation, and
hrombosis. Activated endothelial cells, on the other hand,
roduce reactive oxygen species, such as superoxide (O2
),
hich promote atheroma formation via leukocyte migration
nd infiltration, neointimal hyperplasia, and platelet aggre-
ation (86). High-density lipoprotein cholesterol has been
hown to promote endothelial generation of NO in vitro
nd improve endothelial function and arterial vasoreactivity
n vivo (50), providing another potential antiatherogenic
echanism and a basis for assessing the effects of HDL-
argeted therapies.
Studies (50,87) have clearly demonstrated the ability of
DL added to endothelial cells in culture to significantly
nhance NOS activity in a manner that is dependent on
R-BI. Assaying endothelial NO production in response to
DL could provide the basis of an in vitro proxy of
Figure 5 Lipid Oxidation
(A) Dichlorofluorescein (DCF), a fluorescent marker of lipid oxidation products, is a
mildly oxidized HDL, such as 1-palmitoyl-2(5-oxovaleroyl)-sn-glycero-3-phosphorylcho
(PEIPC), are added to assess the ability of HDL to inactivate biologically active pho
added to a mixture of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PA
enoic acid (HPODE) or hydroperoxyeicosatetraenoic acid (HPETE). After the reagen
fluorescence intensity signaling fewer oxidized phospholipids and suggesting a mo
dant activity in the presence of HDL by that observed in the absence of HDL. The
to antagonize monocyte chemotaxis and lipid oxidation compared with control sub
apy. Figure illustrations by Rob Flewell. Abbreviations as in Figures 1 and 2.ndothelial function and permit assessment of this poten- sially important function of HDL. In principle, basal
ndothelial production of nitrite and nitrate is generated by
ncubating endothelial cells with L-arginine, the substrate
f nitric oxide synthase (NOS), and stimulated production
s achieved through simultaneous addition of an NOS
gonist (Fig. 6A). The NO synthase activity may be
etermined by measuring NOS conversion of [3H]L-
rginine to [3H]L-citrulline via scintillation counting (88)
r by quantifying production of nitrite and nitrate via ozone
hemiluminescence (89). To stimulate endothelial produc-
ion of the oxygen free radical O2
, endothelial cells are
ncubated with a NOS inhibitor, thereby inhibiting free-
adical scavenging capacity, and the concentration of O2
 is
easured (90). Using this cell-based assay, enhanced NOS
ctivity, NO production, and diminished O2
 generation
chieved by the test agent suggest restorative effects on
ndothelium and thus an antiatherogenic benefit.
This approach has been used to assess the efficacy of
DL-based interventions. The apoA-I mimetic L-4F in-
reased endothelial cell NO generation under basal and stim-
lated conditions and attenuated LDL-induced increases in
ndothelial cell O2
 generation (Fig. 6B) (90). A subsequent
to test HDL isolated from patient serum (85). Oxidized phospholipids found in
OVPC) and 1-palmitoyl-2(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphorylcholine
ipids. To assess the ability of HDL to prevent phospholipid oxidation, HDL is
m unoxidized LDL and the endothelium-derived oxidants hydroperoxyoctadecadi-
combined, spectroscopy permits quantification of net oxidation, with diminished
iatherogenic HDL. (B) The “inflammatory index” is derived by dividing net antioxi-
btained from coronary artery disease (CAD) patients exhibits an impaired ability
5). The atheroprotective effect of HDL is partially restored following statin ther-dded
line (P
sphol
PC) fro
ts are
re ant
HDL o
jects (7tudy (91) correlated these in vitro findings with an improved
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June 10, 2008:2199–211 Beyond HDL-C: Evaluating Functionalityasodilatory response to acetylcholine in hypercholesterolemic,
DL receptor-null mice. Administration of the apoA-I mi-
etic oral D-4F in the same mouse model restored NO and
2
 balance in the presence of the proatherogenic oxysterol
2(R)-hydroxycholesterol, which was again shown to reflect
nhanced vasodilatory activity (91).
Vasoreactivity is the most common method of assessing
ndothelial function in vivo and is usually studied in humans
sing ultrasound imaging of the brachial artery at baseline
nd during reactive hyperemia (92). Longitudinal images
re initially obtained after a 10-min equilibration period
ith patients in a fully recumbent position. A blood-
ressure cuff is then placed proximal to the transducer on
he upper arm and inflated to suprasystolic pressure. After 5
in of occlusion, the blood-pressure cuff is deflated and the
rachial artery scanned continuously for 60 s. Finally,
ow-mediated dilation (FMD) is calculated as the maxi-
um percent increase in brachial artery diameter after 1 min
f reactive hyperemia. In observational studies of patients
ith established CAD (93,94), patients with atherosclerotic
isk factors (95,96), and healthy subjects (97), the extent of
MD has consistently correlated with HDL-C levels.
easurement of brachial artery vasodilatation has been used
o evaluate various antidyslipidemic therapies (98). Studies
f HDL-directed therapies have utilized FMD as a proxy of
ndothelial protection. In hypercholesterolemic patients,
econstituted HDL augmented both FMD assessed by
ltrasound and acetylcholine-induced increases in forearm
Figure 6 Endothelial Cell NO Generation and Vasodilation
(A) Basal endothelial production of nitrite and nitrate is generated by incubating e
presence of test serum/HDL (50,88–90). Stimulated production is achieved throu
lial production of free radicals, endothelial cells are incubated with an NOS inhibit
ing capacity, and the concentration of O2
 is measured. Using this cell-based assa
achieved by the test serum/HDL suggest restorative effects on endothelium and t
cultured endothelial cells coincubated with LDL in the presence or absence of the
trations by Rob Flewell. eNOS  endothelial nitric oxide synthase; other abbreviatilood flow, another measure of vasoreactivity (99). Treat- pent with niacin augmented FMD among dyslipidemic
atients with CAD compared with control subjects
92,100).
Although FMD has been suggested to have prognostic
alue (101), change in FMD following pharmacotherapy
as never been correlated with cardiovascular outcomes.
idespread application of FMD as a surrogate measure in
rug development, including HDL-targeted therapies, will
equire further validation in intervention studies to ensure
ts clinical relevance following pharmacotherapy.
The complexity of endothelial pathophysiology in ath-
rosclerosis necessitates additional measures of endothelial
ctivities and function. Developments in the vascular labo-
atory promise a rich array of techniques for the assessment
f vasoreactivity in large conduit vessels and the microvas-
ulature, including pulse-wave analysis, contour analysis,
nd amplitude tonometry. Regarding in vitro assays, eval-
ating upstream effects of isolated HDL after an inter-
ention on NOS activation and localization in caveolae,
pecialized plasma membrane microdomains containing a
ariety of signal transduction molecules, may also prove
nformative (102). Finally, apart from preserving NO and
2
 balance, HDL exerts other putatively atheroprotec-
ive effects on endothelial cells, promoting their prolifer-
tion and migration (103) and inhibiting their apoptosis
104). Ongoing studies will further elucidate techniques
o assess endothelial effects mediated by HDL and clarify
heir utility as reliable biomarkers in the setting of
lial cells with L-arginine, the substrate of nitric oxide synthase (NOS), in the
ultaneous addition of an NOS agonist, such as A23187. To stimulate endothe-
h as L-nitroarginine-methylester (L-NAME), thereby inhibiting free-radical scaveng-
anced NOS activity, nitric oxide (NO) production, and diminished O2
 generation
antiatherogenic benefit. (B) The apoA-I mimetic L-4F restores NO production in
gonist A23187 (90). Reprinted, with permission, from Ou et al. (90). Figure illus-
in Figures 1 and 2.ndothe
gh sim
or, suc
y, enh
hus an
NOS a
ons asharmacotherapy.
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nd Antithrombotic Activity
igh-density lipoprotein cholesterol may provide additional
ardiovascular benefits by antagonizing platelet activity and
nactivating the coagulation cascade, both through direct inhi-
ition and via restoration of endothelial function (50). Early in
itro studies (105–108) demonstrated the ability of purified or
econstituted HDL to inhibit serotonin release and aggrega-
ion of platelet preparations, contrary to the prothrombotic
ffect of LDL. A recent experiment (109) recapitulated these
ndings in a novel setting, showing that HDL adsorbed onto
ynthetic polymeric surfaces inhibited thrombin generation
nd formation at the blood-biomaterial interface. More limited
nimal and human data exist regarding the role of HDL in
hrombosis. Employing a rat model of aortic thrombosis, one
re-clinical trial (110) demonstrated that administration of
poA-I Milano significantly delayed time to thrombus forma-
ion, inhibited platelet aggregation, and reduced the weight of
hrombus produced. In a human study of hyperlipidemic and
ormolipidemic patients without significant coronary risk fac-
ors (111), high HDL-C levels were associated with reduced
hrombus in an ex vivo model. Clot formation, evaluated by
xposing porcine aortic intima to flowing, nonanticoagulated
enous blood from test subjects, varied inversely to HDL-C in
nivariate and multivariable analyses. Human studies (112)
ave demonstrated a significant association between HDL
eficiency and venous thromboembolism.
Within the intricate cascade of hemostasis and thrombo-
is, a multiplicity of interacting factors complicates deter-
ination and prioritization of clinically relevant, HDL-
pecific pathways. Studies thus far (113,114) implicate the
erine protease protein C, a major physiologic anticoagulant
hat inactivates factors Va and VIIIa in plasma. Using a
odified prothrombin time clotting assay, one experiment
115) demonstrated that HDL significantly enhanced inac-
ivation of coagulation factor Va by activated protein C and
rotein S, and levels of apoA-I correlated with the antico-
gulant response. Further support of the importance of
rotein C arose from a rabbit model of atherosclerosis, in
hich short-term infusion of reconstituted HDL reduced
ortic atheroma burden and doubled expression of throm-
omodulin, a cofactor for thrombin-induced activation of
rotein C (116). Evidence suggests that HDL may exert
ntithrombotic activity via inhibition of tissue factor expres-
ion, factor X activation, and plasminogen activator inhib-
tor secretion as well (117–119).
Surrogate measures of HDL antiplatelet and antithrom-
otic functionality remain underdeveloped, in large part
ecause of the absence of consensus regarding the clinically
elevant atheroprotective pathways, and none have been
onsistently employed or correlated with plaque burden or
orphology. It is important to note the accumulating
vidence implicating platelet activation and thrombin gen-
ration in the chronic progression of atheroma (120 –123),
s well as the final, catastrophic event of acute coronaryyndrome and other atherothrombotic diseases. These data
upport a critical role of platelets and the coagulation
ascade in the ongoing progression of atherosclerosis and
ighlight the importance of elucidating HDL-mediated
athways and developing reliable metrics of antiplatelet and
ntithrombotic activity.
onclusions
hanges in circulating HDL-C levels in response to HDL-
argeted therapeutic interventions represent an inadequate
easure of impact on atherosclerotic risk, and better mea-
ures of HDL function are needed. Change in the choles-
erol efflux capacity of serum or HDL ex vivo or cholesterol
ux from tissues in vivo following pharmacotherapeutic
nterventions may provide one approach to assessing the
CT-promoting effects of a new therapy. Indexes of in-
ammation, oxidation, monocyte chemotaxis, NO produc-
ion, endothelial function, and thrombosis reveal other
imensions of HDL functionality. Robust reproducible
ssays that can be performed easily are needed to move this
eld forward. Several clinical and animal studies provide
ope for a new generation of metrics of HDL functionality.
he hope is that detailed compositional assessment of
DL, including both lipid and protein components, cou-
led with sophisticated measures of HDL function, may
ield mass-based biomarkers that can serve as proxies for
unction and that can then be applied with much greater
ase and precision to large populations and clinical trials.
dditional data are required to corroborate preliminary
ssociations among novel HDL assays, mass-based proxies
f function, and atherosclerotic risk to firmly establish
eliable surrogate measures and ultimately facilitate compre-
ensive assessment of HDL-directed drugs in development.
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